
垯ç¶ç±ç¹ã¯ã¯ãã³ã®æ°è£œåã2äž6000äººèŠæš¡ã®è©Šéšã§æå¹ç91.6%
ãNature Communicationsãã«çºè¡šãããã40æ³ä»¥äžã®æäºº2äž6018人ã察象ãšãã第3çžè©Šéšã§ãLZ901ã¯ã¯ãã³ã¯åž¯ç¶ç±ç¹ã«å¯ŸããŠ91.6%ã®æå¹æ§ã瀺ãããä¿è·å¹æã¯å¹Žéœ¢å±€ã«ãã£ãŠåäžã§ã¯ãªãã40ã69æ³ã®æäººã§ã¯æå¹çã93.9%ã«éããäžæ¹ã70æ³ä»¥äžã§ã¯66.9%ã«äœäžããã ãã®è©Šéšã¯ChiCTR2300076253ãšããŠç»é²ãããäžåœã§å®æœããã倿œèšå ±åã»ç¡äœçºåã»äºéç²æ€ã»ãã©ã»ãå¯Ÿç §è©Šéšã§ãããåèš1äž3010人ãã¯ã¯ãã³æ¥çš®çŸ€ã«ã1äž3008人ããã©ã»ã矀ã«å²ãåœãŠããããååå è ã¯30æ¥ééã§2åã®çèå æ¥çš®ãåãã12ãæé远跡ãããããã®æéäžãã¯ã¯ãã³çŸ€ã§15äŸããã©ã»ã矀ã§178äŸã®ç¢ºå®åž¯ç¶ç±ç¹çäŸãçºçãããã®å·®ãã95%ä¿¡é Œåºé86.3%ã95.3%ã®91.6%ãšããæå¹çãç®åºãããã LZ901ã¯ãæ°Žçã»åž¯ç¶ç±ç¹ãŠã€ã«ã¹ã®ç³ã¿ã³ãã¯è³ªEãšããæäœå®åžžé åã®æçãé£çµããèåã¿ã³ãã¯è³ªããäœãããæ°Žé žåã¢ã«ãããŠã ã¢ãžã¥ãã³ãã§è£œå€åãããçµæããµããŠãããã¯ã¯ãã³ã§ããããã®èšèšã¯ããŠã€ã«ã¹ã现èéã§æ¡æ£ããããã«å¿ èŠãªã¿ã³ãã¯è³ªã§ããgEã«å¯Ÿãã匷ãæäœå¿çãšT现èå¿çãèªå°ããããšãæå³ããŠããã匱æ¯åçã¯ã¯ãã³ã§ããæ¢åã®åž¯ç¶ç±ç¹ã¯ã¯ãã³ãšã¯ç°ãªããæ¢åã®ã¢ãžã¥ãã³ãæ·»å çµæãã¯ã¯ãã³ãšåããµããŠãããæ¹åŒãæ¡çšããŠããããæåæ§é ãšééã®ã³ã³ã»ããã¯ç°ãªãèšèšã«åºã¥ãã èšåºçã«æãéèŠãªç¥èŠã¯åž¯ç¶ç±ç¹åŸç¥çµçïŒPHNïŒã«é¢ãããã®ã§ãããPHNã¯çºç¹ãæ²»çããåŸãæ°ãæããæ°å¹Žç¶ãå¯èœæ§ã®ããæ ¢æ§ç¥çµçã ãã¯ã¯ãã³çŸ€ã®åž¯ç¶ç±ç¹15äŸã®ãã¡1äŸãPHNãçºçããã®ã«å¯Ÿãããã©ã»ã矀ã®187äŸã§ã¯24äŸãçºçãããããã¯PHNã«å¯Ÿããæå¹ç95.5%ã«çžåœããã€ãã³ãæ°ãå°ãªãããä¿¡é Œåºéã¯63.9%ã99.9%ãšå¹ ãåºãã å®å šæ§ããŒã¿ã¯å šäœãšããŠè¯å¥œã ã£ããã¯ã¯ãã³æ¥çš®è ã§ã¯åé±ä»¥å ã«æ³šå°éšäœåå¿ãšå šèº«æ§åå¿ãå€ãå ±åãããããããã¯å ç«ç³»ã«åããããã¯ã¯ãã³ã§ããã°åœç¶ã®åå¿ã§ãããã°ã¬ãŒã3ã®åå¿ã¯LZ901矀ã§0.3%ããã©ã»ã矀ã§0.4%ã«çºçããçµ±èšçã«å·®ã¯èªããããªãã£ããã¯ã¯ãã³ã«èµ·å ããéç¯€ãªæå®³äºè±¡ã¯ãªãã£ãã 幎霢ã«ãã广ã®å·®ã¯å ¬è¡è¡çäžéèŠã§ãããå ç«å¿çã¯å 霢ãšãšãã«åŒ±ãŸããè¥ãæäººã«é«ã广ã瀺ãã¯ã¯ãã³ã§ãã垯ç¶ç±ç¹ãšãã®å䜵çã®ãªã¹ã¯ãæãé«ãé«éœ¢è å±€ã§ã¯å¹æãéå®çã«ãªãããšãå€ãããã ã70æ³ä»¥äžã§ã®66.9%ãšããæå¹çã¯ãä¿¡é Œåºéã14.6%ã89.2%ã«åã³ãæ¯èŒçå°æ°ã®çäŸã«åºã¥ããã®ã§ãããããæ éã«è§£éãã¹ãã ãæ¢åã®ã¢ãžã¥ãã³ãæ·»å çµæãã¯ã¯ãã³ã¯äž»èŠè©Šéšã§é«éœ¢è ã«å¯Ÿããé«ãæå¹æ§ã瀺ããŠããããã®å¹Žéœ¢å±€ã«ããã2ã€ã®ãµããŠãããæ¹åŒã®çŽæ¥æ¯èŒè©Šéšãå¿ èŠã«ãªãã ããã ãã®è©Šéšã¯äžåœã®åœå®¶ç ç©¶ããã°ã©ã ã®è³éæäŸãåããå京ã«ãŒãºãŒã»ãã€ãªãã¯ãããžãŒãéçºãããæ²»éšæ åœè ã¯äžåœåçã®çŸç 察çã»ã³ã¿ãŒïŒCDCïŒãããã¯ãŒã¯ãšåŠè¡æ©é¢ããåå ããŠããã12ãæéã®è¿œè·¡ã¯çæçãªäºé²å¹æãšããåœé¢ã®çåã«çãããã®ã ããæ°å¹Žã«ãããæç¶æ§ãšè¿œå æ¥çš®ã®èŠåŠã¯ä»åŸæããã«ããå¿ èŠãããã é å èš³ Sources: Jin, P., Quan, Y., Gao, X. et al. The efficacy, immunogenicity and safety of the LZ901 vaccine for herpes zoster virus in adults 40 years of age or older: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Nature Communications (2026). DOI: 10.1038/s41467-026-76313-w.









